NasdaqGS:GILDBiotechs
Gilead Leans Further Into Oncology With Arcellx And Tubulis Deals
Gilead Sciences (NasdaqGS:GILD) has received all required regulatory approvals to close its US$7.8b acquisition of Arcellx.
The company also announced an agreement to acquire Tubulis GmbH to expand its oncology pipeline with antibody drug conjugate technology.
Both transactions are described as meaningful for Gilead's cell therapy and cancer treatment ambitions.
For investors, these deals highlight how Gilead is leaning further into oncology alongside its established presence in antiviral...